2-Chlorodeoxyadenosine and cytarabine combination therapy for idiopathic hypereosinophilic syndrome-Reference-Cited by-同舟云学术

2-Chlorodeoxyadenosine and cytarabine combination therapy for idiopathic hypereosinophilic syndrome

Published:2005 Issue:3 Volume:104 Page:541-546
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Jabbour Elias,Verstovsek Srdan,Giles Francis,Gandhi Varsha,Cortes Jorge,O'Brien Susan,Plunkett William,Garcia-Manero Guillermo,Ellen Jackson C.,Kantarjian Hagop,Andreeff Michael

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference31 articles.

1. THE HYPEREOSINOPHILIC SYNDROME

2. The idiopathic hypereosinophilic syndrome

3. Imatinib therapy for hypereosinophilic syndrome and eosinophilia-associated myeloproliferative disorders

4. The Hypereosinophilic Syndrome and the Biology of Cancer

5. Clonal nature of hypereosinophilic syndrome [letter]

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management;American Journal of Hematology;2024-03-29

2. World Health Organization‐defined eosinophilic disorders: 2022 update on diagnosis, risk stratification, and management;American Journal of Hematology;2021-10-08

3. Clinical and morphologic spectrum of renal involvement in idiopathic hypereosinophilic syndrome;Clinical and Experimental Nephrology;2021-01-04

4. World Health Organization‐defined eosinophilic disorders: 2019 update on diagnosis, risk stratification, and management;American Journal of Hematology;2019-09-10

5. World Health Organization-defined eosinophilic disorders: 2017 update on diagnosis, risk stratification, and management;American Journal of Hematology;2017-10-17